Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis by Choudhury, Rashikh, Barrett, Christopher D., Moore, Hunter B., Moore, Ernest E., McIntyre, Robert C., Moore, Peter K., Talmor, Daniel S., Nydam, Trevor L., Yaffe, Michael B.

Get full text

Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): A case series by Wang, Janice, Hajizadeh, Negin, Moore, Ernest E., McIntyre, Robert C., Moore, Peter K., Veress, Livia A., Yaffe, Michael B., Moore, Hunter B., Barrett, Christopher D.

Get full text

STudy of Alteplase for Respiratory failure in SARS‐Cov2/COVID‐19: Study Design of the Phase IIa STARS Trial by Moore, Hunter B., Barrett, Christopher D, Moore, Ernest E., Jhunjhnuwala, Rashi, McIntyre, Robert C., Moore, Peter K, Wang, Janice, Hajizadeh, Negin, Talmor, Daniel S., Sauaia, Angela, Yaffe, Michael B

Get full text

Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review by Barrett, Christopher D., Moore, Hunter B., Moore, Ernest E., McIntyre, Robert C., Moore, Peter K, Burke, John, Hua, Fei, Apgar, Joshua, Talmor, Daniel S., Sauaia, Angela, Liptzin, Deborah R., Veress, Livia A., Yaffe, Michael B.

Get full text